Mar 10, 2020 / 02:45PM GMT
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior Analyst
All right. Good morning. I'm Carter Gould, senior biopharma analyst here at Barclays. I'm delighted to welcome Eli Lilly to the Barclays Virtual Global Health Care Conference. Today represents a great opportunity to go a bit deeper on the Lilly Diabetes franchise as I'm joined today by Dr. Jeff Emmick, VP of Diabetes Product Development; and Ilya Yuffa, VP of U.S. Diabetes on the commercial side. We've also got Mike Czapar from the Lilly IR squad on the phone. I -- before we get started, I want to, first of all, thank Lilly and all the investors, for everyone's patience surrounding logistics overall here, and we're set up for good conversation.
Questions and Answers:
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior AnalystMaybe to set the stage, guys. We're going to get to all the relevant individual products and some of the later-stage pipeline opportunities. But just from a broader perspective, when Eli Lilly sort of sits down and thinks about the Diabetes
Trustpilot
